<DOC>
	<DOCNO>NCT02743351</DOCNO>
	<brief_summary>This study Phase 1 Non-randomized/Phase 2 Randomized , open-label , prospectively historically control trial safety efficacy single ProTmune ex vivo program mobilized peripheral blood ( mPB ) cell hematopoietic cell transplantation ( HCT ) adult subject age 18 70 year hematologic malignancy . A maximum 70 total eligible subject enrol treated trial approximately 10-12 center US EU .</brief_summary>
	<brief_title>Study ProTmune Allogeneic HCT Adult Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Key 1 . Male female patient age 18 70 year , inclusive ; 2 . Patients must CMV seropositive evidence detectable CMV replication baseline ; 3 Patients must hematologic malignancy allogeneic hematopoietic peripheral blood cell transplantation deem clinically appropriate . Eligible disease stage include follow : 1 . Acute myeloid leukemia 2 . Acute lymphoblastic leukemia , include T lymphoblastic lymphoma history marrow involvement 3 . Myelodysplatic Syndrome ( Phase 2 portion study ) 4.Availability suitable 8/8 HLAA , B , C , DRB1matched unrelated mPB donor ; 5.Adequate performance status , define Karnofsky score great 70 % ; 6.For female patient childbearing potential , follow criterion must meet : They pregnant ( i.e. , female patient must negative serum pregnancy test screening ) ; They breastfeed ; They plan become pregnant study ; They use effective method contraception screen end study , unless sexual partner surgically sterile 7.For male patient , agreement use condom spermicide sexual intercourse screen end study ; 8.Willingness ability sign IRB/IEC approve ICF performance study specific procedure test comply protocol visit , study procedure . Key 1 . Positive serology human immunodeficiency virus ( HIV ) human Tcell lymphotropic virus ( HTLV ) time prior enrollment ; 2 . Currently active bacterial , viral , fungal infection ( progression clinical symptom despite therapy ) ; 3 . Prior autologous allogeneic HCT ; 4 . Secondary treatmentrelated hematologic malignancy ; 5 . Active malignancy , one allogeneic mPB transplant perform , within 12 month enrollment , exclude superficial basal cell carcinoma situ cervical cancer ; 6 . Pulmonary disease , renal dysfunction , hepatic disease , cardiac disease , neurologic disease ; 7 . Participation another clinical trial involve investigational product within 30 day prior screen ; 8 . Any condition therapy , , opinion Investigator , might pose risk patient make participation study best interest patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cell Transplants</keyword>
	<keyword>Hematopoietic Cell Transplant</keyword>
	<keyword>HCT</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Hematologic Malignancy</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
</DOC>